MSME (Udyam registered) Ministry of MSME
- Category
- Small (2024-25)
- Udyam number
- UDYAM-MH-19-0021173
Market Cap
₹30.18 Cr
CBPL · BSE
Share Price
₹40.00
0.00% today
Revenue
₹116 Cr
FY 2025-26 · +30.9% YoY
EBITDA
₹3.86 Cr
Margin 3.3%
Net Profit
₹3.05 Cr
FY 2025-26 · +335.7% YoY
P/E (TTM)
9.9x
P/B 0.9x
ROE
9.7%
ROCE 12.2%
Debt / Equity
0.59
Interest cover 72.5x
About Chandra Bhagat Pharma Limited
Data last updated:
Chandra Bhagat Pharma Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 10 March 2003 and has been in existence for over 23 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24230MH2003PLC139534. Its GSTIN is 27AACCC1056D1Z6 (Maharashtra). The company holds 3 GST registrations, of which 1 is active. Its shares are listed on BSE: 542934.
The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹7.55 Cr. It was formerly known as Chandra Bhagat Pharma Private Limited. It is led by directors including Hemant Chandravadan Bhagat (Managing Director) and Pranav Hemant Bhagat (Whole-Time Director).
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 323 – F Bhagat Bhuvan Dr.Ambedkar Road Matunga (East), Mumbai, Maharashtra, India – 400019.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹116.27 Cr, a growth of 30.9% compared to the previous year. For the same year it recorded a net profit of ₹3.05 Cr (net margin 2.6%) and EBITDA of ₹3.86 Cr (EBITDA margin 3.3%). The net worth stands at ₹33.13 Cr (up 10.5% YoY). Total assets are valued at ₹49.66 Cr (down 2.4% YoY).
The company has about 31 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Chandra Bhagat Pharma. As per MCA filings, the company has open charges of ₹47.5 Cr and satisfied charges of ₹41.15 Cr on record. Court records list 28 cases involving the company, including 4 filed by the company and 23 filed against it; 6 cases are pending. The company has 63 deals on record (62 market trades, 1 ipo); the latest was in June 2026. Its 10 peer companies in the Pharma industry (Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is Chiron Behring Vaccines Private Limited with revenue of ₹94.53 Cr.
Chandra Bhagat Pharma Limited is registered as a small enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-19-0021173). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website cbcpharma.com.
Company Details of Chandra Bhagat Pharma Limited
CIN L24230MH2003PLC139534
Registration Number 139534
Incorporation Date 10 March 2003
ROC Mumbai
Listing Status Listed (BSE: 542934)
Company Status Active
Date of Last AGM 30 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Small
Udyam Registration UDYAM-MH-19-0021173
CIN History of Chandra Bhagat Pharma Limited
Chandra Bhagat Pharma has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24230MH2003PLC139534, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230MH2003PLC139534 | Current |
| U24230MH2003PTC139534 | Previous |
| U24230MH2003PLC139534 | Previous |
Key People
Hemant Chandravadan Bhagat Managing Director Pranav Hemant Bhagat Whole-Time Director Ravindra Gajanan Awati Director Recognitions & Rankings of Chandra Bhagat Pharma
Contact Details
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered Address323 – F Bhagat Bhuvan Dr.Ambedkar Road Matunga (East), Mumbai, Maharashtra, India – 400019
- IndustryPharma, Drug Formulation & Development
Comprehensive company report
Chandra Bhagat Pharma Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Associated Brands with Chandra Bhagat Pharma Limited
Chandra Bhagat Pharma operates one associated brand: Chandra Bhagat Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Importer, exporter, and marketer of pharmaceutical products | cbcpharma.com |
Business Activity of Chandra Bhagat Pharma Limited
The main business activity of Chandra Bhagat Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Premium access
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Chandra Bhagat Pharma Limited FY 2025-26 filings available
Chandra Bhagat Pharma Limited reported revenue of ₹116.27 Cr (up 30.9% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue
₹116 Cr
+30.9% YoY
EBITDA
₹3.86 Cr
+512.7% YoY
Profit After Tax
₹3.05 Cr
+335.7% YoY
Net Worth
₹33.13 Cr
+10.5% YoY
Total Assets
₹49.66 Cr
-2.4% YoY
Total Debt
₹16.51 Cr
-20.9% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 116 | 88.81 | 221 | 120 | 94.08 | 70.70 | 93.98 |
| Revenue growth | +30.9% | -59.9% | +85.0% | +27.2% | +33.1% | -24.8% | - |
| EBITDA | 3.86 | 0.63 | (7.05) | 3.33 | 2.83 | 3.68 | 3.12 |
| EBITDA margin | +3.3% | +0.7% | -3.2% | +2.8% | +3.0% | +5.2% | +3.3% |
| Profit before tax | 4.11 | 1.16 | 2.25 | 1.15 | 1.09 | 0.28 | 0.42 |
| Net profit | 3.05 | 0.70 | 1.51 | 0.90 | 0.79 | 0.19 | 0.31 |
| Net profit margin | +2.6% | +0.8% | +0.7% | +0.8% | +0.8% | +0.3% | +0.3% |
| EPS (₹) | 4.04 | 1.14 | 2.03 | 1.20 | 1.06 | 0.25 | 0.42 |
| Balance sheet | |||||||
| Total assets | 49.66 | 50.86 | 45.76 | 48.64 | 50.10 | 56.52 | 59.71 |
| Net worth | 33.13 | 29.97 | 29.01 | 27.48 | 26.68 | 25.88 | 25.69 |
| Total debt | 16.51 | 20.86 | 16.43 | 18.94 | 21.11 | 27.07 | 29.93 |
| Cash & bank | 3.11 | 0.67 | 4.96 | 6.44 | 5.68 | 2.82 | 0.05 |
| Net working capital | 41.46 | 43.85 | 41.75 | 46.06 | 48.14 | 54.76 | 57.08 |
| Cash flow | |||||||
| Cash from operations | 9.24 | (5.71) | 6.18 | 5.26 | 12.40 | 8.33 | (7.41) |
| Cash from investing | (0.43) | (0.78) | (1.85) | (0.06) | 0.09 | 0.12 | 0.05 |
| Cash from financing | (6.36) | 2.19 | (5.80) | (4.45) | (9.62) | (6.42) | 6.94 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 20 Oct 2026
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 116 | 88.81 | 221 | 120 | 94.08 | 70.70 | 93.98 |
| Revenue growth | +30.9% | -59.9% | +85.0% | +27.2% | +33.1% | -24.8% | - |
| Other income | 3.35 | 3.43 | 11.33 | 0.29 | 1.62 | 0.48 | 0.44 |
| Total expenses | 112 | 88.18 | 228 | 116 | 91.25 | 67.02 | 90.86 |
| Employee cost | 2.53 | 2.03 | 2.18 | 1.32 | 1.52 | 1.85 | 2.25 |
| EBITDA | 3.86 | 0.63 | (7.05) | 3.33 | 2.83 | 3.68 | 3.12 |
| EBITDA margin | +3.3% | +0.7% | -3.2% | +2.8% | +3.0% | +5.2% | +3.3% |
| Depreciation | 1.10 | 0.95 | 0.64 | 0.27 | 0.12 | 0.12 | 0.03 |
| Interest | 2.00 | 1.95 | 1.39 | 2.20 | 3.24 | 3.76 | 3.11 |
| Profit before tax | 4.11 | 1.16 | 2.25 | 1.15 | 1.09 | 0.28 | 0.42 |
| Tax | 1.06 | 0.31 | 0.74 | 0.25 | 0.30 | 0.09 | 0.11 |
| Net profit | 3.05 | 0.70 | 1.51 | 0.90 | 0.79 | 0.19 | 0.31 |
| Net profit margin | +2.6% | +0.8% | +0.7% | +0.8% | +0.8% | +0.3% | +0.3% |
| EPS (₹) | 4.04 | 1.14 | 2.03 | 1.20 | 1.06 | 0.25 | 0.42 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 7.55 | 7.55 | 7.55 | 7.55 | 7.55 | 7.55 | 7.55 |
| Reserves & surplus | 25.58 | 22.42 | 21.46 | 19.93 | 19.13 | 18.33 | 18.14 |
| Shareholders' funds (net worth) | 33.13 | 29.97 | 29.01 | 27.48 | 26.68 | 25.88 | 25.69 |
| Secured loans | 14.64 | 19.09 | 14.64 | 14.37 | 16.12 | 18.82 | 17.66 |
| Unsecured loans | 1.87 | 1.77 | 1.79 | 4.57 | 4.99 | 8.25 | 12.27 |
| Total debt | 16.51 | 20.86 | 16.43 | 18.94 | 21.11 | 27.07 | 29.93 |
| Total liabilities | 49.66 | 50.86 | 45.76 | 48.64 | 50.10 | 56.52 | 59.71 |
| Assets | |||||||
| Gross block | 5.17 | 4.25 | 3.78 | 1.50 | 1.13 | 1.26 | 1.24 |
| Net block | 2.62 | 2.62 | 2.53 | 0.73 | 0.47 | 0.42 | 0.43 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 1.67 | 0.14 | 0.13 | 0.11 | 0.22 | 0.00 | 0.75 |
| Inventories | 4.67 | 0.69 | 8.68 | 29.08 | 34.16 | 35.14 | 43.90 |
| Sundry debtors | 54.62 | 35.95 | 39.45 | 8.19 | 15.00 | 15.42 | 14.03 |
| Cash & bank balances | 3.11 | 0.67 | 4.96 | 6.44 | 5.68 | 2.82 | 0.05 |
| Loans & advances | 23.60 | 57.21 | 44.70 | 14.28 | 15.66 | 16.63 | 14.14 |
| Total current assets | 86.00 | 94.52 | 97.79 | 57.99 | 70.50 | 70.01 | 72.12 |
| Total current liabilities | 44.54 | 50.67 | 56.04 | 11.93 | 22.36 | 15.25 | 15.04 |
| Net working capital | 41.46 | 43.85 | 41.75 | 46.06 | 48.14 | 54.76 | 57.08 |
| Total assets | 49.66 | 50.86 | 45.76 | 48.64 | 50.10 | 56.52 | 59.71 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.67 | 4.96 | 6.44 | 5.68 | 2.82 | 0.80 | 0.48 |
| Net cash from operating activities | 9.24 | (5.71) | 6.18 | 5.26 | 12.40 | 8.33 | (7.41) |
| Net cash from investing activities | (0.43) | (0.78) | (1.85) | (0.06) | 0.09 | 0.12 | 0.05 |
| Net cash from financing activities | (6.36) | 2.19 | (5.80) | (4.45) | (9.62) | (6.42) | 6.94 |
| Net change in cash | 2.45 | (4.30) | (1.48) | 0.76 | 2.86 | 2.02 | (0.43) |
| Closing cash | 3.11 | 0.67 | 4.96 | 6.44 | 5.68 | 2.82 | 0.05 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +30.9% | -59.9% | +85.0% | +27.2% | +33.1% | -24.8% | - |
| EBITDA growth | +512.7% | +108.9% | -311.7% | +17.7% | -23.1% | +18.0% | - |
| PBT growth | +254.3% | -48.4% | +95.7% | +5.5% | +289.3% | -33.3% | -53.3% |
| Net income growth | +335.7% | -53.6% | +67.8% | +13.9% | +315.8% | -38.7% | - |
| Revenue CAGR (3Y) | -1.0% | -1.9% | +46.3% | +8.4% | -4.0% | -10.0% | +1.5% |
| EBITDA CAGR (3Y) | +5.1% | -39.4% | - | +2.2% | -15.0% | -7.1% | -10.6% |
| Profitability & leverage | |||||||
| Net income margin | +2.6% | +1.0% | +0.7% | +0.8% | +0.8% | +0.3% | +0.3% |
| Return on capital employed | +12.2% | +6.0% | +7.7% | +6.8% | +8.1% | +7.0% | +6.4% |
| Return on net worth | +9.7% | +2.4% | +5.4% | +3.4% | +3.0% | +0.7% | +1.5% |
| Debt / equity | 0.59 | 0.63 | 0.63 | 0.74 | 0.92 | 1.11 | 1.52 |
| Long-term debt / equity | 0.08 | 0.06 | 0.09 | 0.17 | 0.28 | 0.39 | 0.56 |
| Interest cover | 72.46 | -609.38 | -18.08 | 71.90 | 119.56 | 105.62 | 100.65 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 24.69 | 22.12 | 83.85 | 91.00 | 78.73 | 56.56 | 75.79 |
| Inventory turnover | 43.38 | 18.96 | 11.73 | 3.78 | 2.72 | 1.79 | 2.14 |
| Debtors turnover | 2.57 | 2.36 | 9.29 | 10.32 | 6.19 | 4.80 | 4.66 |
| EPS (₹) | 4.04 | 1.14 | 2.03 | 1.20 | 1.06 | 0.25 | 0.42 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 43.90 | 39.72 | 38.45 | 36.42 | 35.35 | 34.30 | 34.05 |
Want more history and ratios?
You're viewing the latest exchange-filed financials for Chandra Bhagat Pharma Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
Board of Directors of Chandra Bhagat Pharma Limited
Chandra Bhagat Pharma has 5 current directors and 3 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ravindra Gajanan Awati Also directs: Jagatik Marathi Chamber of Commerce and Industries | Director | 31 Aug 2019 | 7 Years 1 Months | Current |
| Abha Praveen Doshi | Director | 15 Jul 2019 | 7 Years 3 Months | Current |
| Hemant Chandravadan Bhagat | Managing Director | 10 Mar 2003 | 23 Years 7 Months | Current |
| Pranav Hemant Bhagat Also directs: Indo-Persian Gulf Chamber of Commerce | Whole-Time Director | 17 May 2004 | 22 Years 5 Months | Current |
| Prachi Pranav Bhagat Also directs: Indo-Persian Gulf Chamber of Commerce | Director | 25 Sep 2018 | 8 Years 0 Months | Current |
Peer Comparison of Chandra Bhagat Pharma Limited
Chandra Bhagat Pharma Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Chandra Bhagat Pharma Limited this company | ₹116.27 Cr (FY 2026) | •••• | •••• | 30.9% | •••• | Mumbai, Maharashtra, India |
| Chiron Behring Vaccines Private Limited | ₹94.53 Cr (FY 2025) | •••• | •••• | 30.0% | •••• | Bhor, Maharashtra, India |
| Daxin Pharmaceuticals Private Limited | ₹93.78 Cr (FY 2025) | •••• | •••• | 40.0% | •••• | New Delhi, Delhi, India |
| Cosmas Research Lab Limited | ₹93.42 Cr (FY 2025) | •••• | •••• | 60.0% | •••• | Ludhiana, Punjab, India |
| Centurion Healthcare Private Limited | ₹92.65 Cr (FY 2024) | •••• | •••• | 21.0% | •••• | Vadodara, Gujarat, India |
| Lovincare Cosmetics Private Limited | ₹92.22 Cr (FY 2025) | •••• | •••• | 22.0% | •••• | Himachal Pradesh, India |
| Twentyfirst Century Pharmaceuticals Private Limited | ₹91.89 Cr (FY 2022) | •••• | •••• | 32.0% | •••• | Chennai, Tamil Nadu, India |
| Lifecare Neuro Products Limited | ₹91.88 Cr (FY 2024) | •••• | •••• | 14.0% | •••• | Nalagarh, Himachal Pradesh, India |
| Akhil Healthcare Private Limited | ₹91.42 Cr (FY 2025) | •••• | •••• | 32.0% | •••• | Vadodara, Gujarat, India |
| Sydler Remedies Private Limited | ₹91.31 Cr (FY 2025) | •••• | •••• | -30.0% | •••• | Aurangabad, Maharashtra, India |
| S. A. Pharmachem Private Limited | ₹91.25 Cr (FY 2025) | •••• | •••• | -54.0% | •••• | Mumbai, Maharashtra, India |
Peers are the five companies nearest above and the five nearest below Chandra Bhagat Pharma by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Chandra Bhagat Pharma Limited
Chandra Bhagat Pharma Limited is audited by A Y & COMPANY for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| A Y & COMPANY | Locked | Locked | Locked |
Premium access
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Shareholding Pattern of Chandra Bhagat Pharma Limited
Shareholding for the quarter ended Sep 2026: promoters hold 73.00%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 27.00%.
Sep 2026
QUARTER
73.00% Promoters
27.00% Retail & Others
Promoter holding - history
Now 73.00% · Sep 2026High 73.00% · Sep 2026Low 71.20% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 73.00% | 72.20% | 71.20% | 71.20% |
| Public | 27.00% | 27.80% | 28.80% | 28.80% |
Charges & Borrowings of Chandra Bhagat Pharma Limited
Open charges
₹47.5 Cr
Satisfied charges
₹41.15 Cr
Breakdown by lending institutions
Latest charge details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Jul 2026 | Axis Bank Limited | ₹1.62 Cr | Open |
| 13 Jul 2026 | Axis Bank Limited | ₹23.06 Cr | Open |
| 16 Jan 2025 | Canara Bank | ₹30 Lakh | Open |
| 28 Oct 2020 | Axis Bank Limited | ₹3.25 Cr | Open |
| 23 Feb 2018 | Axis Bank Limited | ₹19.27 Cr | Open |
Total charge records: 13 View all charges
Deals & Funding of Chandra Bhagat Pharma Limited
Chandra Bhagat Pharma Limited has 63 deals on record (62 market trades, 1 ipo); the latest was in June 2026.
Total deals
63
Market trades
62
IPO
1
Deals on record (5 of 63)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jun 2026 | Market trade | ₹21.6 Lakh | Seller: Team Anamika Algo Limited |
| May 2026 | Market trade | ₹24.7 Lakh | Buyer: Bengal Tiger Capital Advisors LLP Seller: Team Anamika Algo Limited |
| Nov 2024 | Market trade | ₹44.1 Lakh | Buyer: an individual Seller: Piyush Securities Pvt Ltd |
| Nov 2024 | Market trade | ₹40.9 Lakh | Buyer: Piyush Securities Pvt Ltd Seller: Kapil Agarwal Huf . |
| Nov 2024 | Market trade | ₹71.4 Lakh | Buyer: Sunflower Broking Private Limited Seller: Alacrity Securities Limited , Sunflower Broking Private Limited |
Premium access
Full deal history
All 63 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Chandra Bhagat Pharma Limited
Chandra Bhagat Pharma Limited has 28 court cases on record: 4 filed by Chandra Bhagat Pharma, 23 filed against it, 1 where it is another party. 6 cases are pending and 22 are disposed. Status as checked between 21 Sep 2026 and 04 Oct 2026.
Total cases
28
Filed by the company
4
Filed against the company
23
Pending
6
Disposed
22
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 23 | 22 | 3 |
| High courts | 5 | 1 | 3 |
Cases on record (5 of 28)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Rajasthan | Court case (CSTAY) | Filed by the company against Rajasthan Medical Services Corporation Limited | Pending |
| High Court of Rajasthan | Court case (CFA) | Filed by the company against Rajasthan Medical Services Corporation Limited | Pending |
| High Court of Rajasthan | Court case (CMCC) | Filed by the company against Rajasthan Medical Services Corporation Limited | Disposed |
| District court, Mumbai City Civil Court, Maharashtra | Commercial matter | Filed against the company by Gufic Biosciences Limited | Disposed |
| Bombay High Court | Court case (EXA) | Filed against the company by Kotak Mahindra Bank Limited | Disposed |
Premium access
Full case history
All 28 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
Employees and EPFO Compliance at Chandra Bhagat Pharma Limited
Chandra Bhagat Pharma Limited has a workforce of 31 employees as of Apr 02, 2024.
Employee count
31
Active EPFO establishments
1
Employee growth
24%
Premium access
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Chandra Bhagat Pharma Limited
Chandra Bhagat Pharma Limited has 9 board changes on record since 2003: 7 appointments and 2 cessations. The latest: Ravindra Gajanan Awati was appointed as Director on 31 Aug 2019.
Charges
A charge with Axis Bank Limited of Rs. 23.06 Cr registered on 13 Jul 2026 with Charge ID 101338774 was modified on 24 Sep 2026.
Charges
A charge with Axis Bank Limited amounted to Rs. 1.62 Cr with Charge ID 101357317 was registered on 29 Jul 2026.
Charges
A charge with Axis Bank Limited amounted to Rs. 23.06 Cr with Charge ID 101338774 was registered on 13 Jul 2026.
AGM
Chandra Bhagat Pharma Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Filing
Chandra Bhagat Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Mumbai I.
Charges
A charge with Canara Bank amounted to Rs. 0.30 Cr with Charge ID 101049748 was registered on 16 Jan 2025.
Charges
A charge registered on 11 Sep 2017 via Charge ID 100130761 with Others was fully satisfied on 11 Nov 2024.
Charges
A charge with Axis Bank Limited of Rs. 19.27 Cr registered on 23 Feb 2018 with Charge ID 100162599 was modified on 28 Jun 2024.
Charges
A charge with Axis Bank Limited of Rs. 3.25 Cr registered on 28 Oct 2020 with Charge ID 100396299 was modified on 06 Feb 2021.
Charges
A charge with Axis Bank Limited amounted to Rs. 3.25 Cr with Charge ID 100396299 was registered on 28 Oct 2020.
Appointed
Ravindra Gajanan Awati was appointed as Director.
Appointed
Abha Praveen Doshi was appointed as Director.
27 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Chandra Bhagat Pharma Limited
Premium access
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Chandra Bhagat Pharma Limited
Premium access
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Chandra Bhagat Pharma Limited
Premium access
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Chandra Bhagat Pharma Limited
Chandra Bhagat Pharma has 3 GST registrations: 1 active and 2 cancelled or inactive.
Total GSTINs
3
Active
1
Cancelled / inactive
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AACCC1056D1Z6 | Maharashtra | Active | 01 Jul 2017 |
Premium access
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Chandra Bhagat Pharma Limited
Premium access
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Related news about Chandra Bhagat Pharma Limited
Frequently Asked Questions about Chandra Bhagat Pharma Limited
Chandra Bhagat Pharma is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 10 March 2003 (23+ years old) and is registered under CIN L24230MH2003PLC139534. Listed on BSE: 542934.
Chandra Bhagat Pharma reported revenue of ₹116.27 Cr for FY 2025-26 (up 30.9% YoY) based on standalone financials.
Chandra Bhagat Pharma has 5 current directors:
- Hemant Chandravadan Bhagat - Managing Director
- Pranav Hemant Bhagat - Whole-Time Director
- Ravindra Gajanan Awati - Director
- Abha Praveen Doshi - Director
- Prachi Pranav Bhagat - Director
The GSTIN of Chandra Bhagat Pharma is 27AACCC1056D1Z6, registered in Maharashtra. The company has 3 GST registrations in all, of which 1 is active and 2 are cancelled or inactive.
The CIN (Corporate Identification Number) of Chandra Bhagat Pharma is L24230MH2003PLC139534. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Chandra Bhagat Pharma is listed on BSE with code 542934.
Chandra Bhagat Pharma has 28 court cases on record: 4 filed by the company and 23 filed against it. 6 are pending. Most are in the district courts.
Chandra Bhagat Pharma was incorporated on 10 March 2003, making it 23+ years old. It is registered with the Registrar of Companies, Mumbai.
Chandra Bhagat Pharma has 63 deals on record (62 market trades, 1 ipo); the latest was in June 2026.
The peers of Chandra Bhagat Pharma by revenue are Chiron Behring Vaccines Private Limited, Daxin Pharmaceuticals Private Limited, Cosmas Research Lab Limited, Centurion Healthcare Private Limited, Lovincare Cosmetics Private Limited and 5 more, all in the Pharma industry (Formulations).
Ravindra Gajanan Awati was appointed as Director on 31 Aug 2019. Abha Praveen Doshi was appointed as Director on 15 Jul 2019. Prachi Pranav Bhagat was appointed as Director on 25 Sep 2018. Chandra Bhagat Pharma has 9 board changes on record in total.